Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NXTC NextCure Inc
- Stocks
- Healthcare
- NASDAQ: NXTC
Price (delayed)
$0.4174
Market cap
$11.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.76
Enterprise value
-$5.21M
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through its proprietary FIND-IO™ platform, NextCure studies various immune
Highlights
The EPS has grown by 23% YoY and by 12% from the previous quarter
NXTC's net income is up by 22% year-on-year and by 11% since the previous quarter
The quick ratio has grown by 36% from the previous quarter but it has contracted by 2.9% YoY
NextCure's equity has decreased by 44% YoY and by 15% QoQ
Key stats
What are the main financial stats of NXTC
Market
Valuations
Earnings
Shares outstanding
28.05M
Market cap
$11.71M
Enterprise value
-$5.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.21
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$53.07M
Net income
-$49.52M
EBIT
-$49.52M
EBITDA
-$46.24M
Free cash flow
-$41.63M
Per share
Balance sheet
Liquidity
EPS
-$1.76
EPS diluted
-$1.76
Free cash flow per share
-$1.49
Book value per share
$1.99
Revenue per share
$0
TBVPS
$2.4
Total assets
$67.14M
Total liabilities
$11.28M
Debt
$4.91M
Equity
$55.86M
Working capital
$53.16M
Debt to equity
0.09
Current ratio
10.26
Quick ratio
9.73
Net debt/EBITDA
0.37
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-58.1%
Return on equity
-70.2%
Return on invested capital
-86.5%
Return on capital employed
-80.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NXTC stock price
How has the NextCure stock price performed over time
Intraday
-4.27%
1 week
-10.45%
1 month
-13.1%
1 year
-72.17%
YTD
-45.86%
QTD
-9.26%
Financial performance
How have NextCure's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$53.07M
Net income
-$49.52M
Gross margin
N/A
Net margin
N/A
NextCure's operating income has increased by 23% YoY and by 11% from the previous quarter
NXTC's net income is up by 22% year-on-year and by 11% since the previous quarter
Price vs fundamentals
How does NXTC's price correlate with its fundamentals
Growth
What is NextCure's growth rate over time
Valuation
What is NextCure stock price valuation
P/E
N/A
P/B
0.21
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 23% YoY and by 12% from the previous quarter
The P/B is 63% lower than the 5-year quarterly average of 0.6 and 45% lower than the last 4 quarters average of 0.4
NextCure's equity has decreased by 44% YoY and by 15% QoQ
Efficiency
How efficient is NextCure business performance
NextCure's return on invested capital has shrunk by 55% YoY and by 8% QoQ
NXTC's return on equity is down by 32% year-on-year and by 2.6% since the previous quarter
NXTC's ROA is down by 22% YoY
Dividends
What is NXTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NXTC.
Financial health
How did NextCure financials performed over time
NXTC's total assets is down by 42% year-on-year and by 17% since the previous quarter
NXTC's current ratio is up by 37% since the previous quarter but it is down by 4.1% year-on-year
NXTC's debt is 91% smaller than its equity
The debt to equity has surged by 50% year-on-year and by 13% since the previous quarter
NextCure's equity has decreased by 44% YoY and by 15% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.